Mepolizumab reduces healthcare resource utilization in patients with chronic rhinosinusitis with nasal polyps: a linked EMR and claims-based pre-post study
Anna Swenson, Waseem Ahmed, Jared Silver, Shiyuan Zhang, Amy Edgecomb, Lingjiao Zhang, Rafael Alfonso-Cristancho, Richard Gliklich · 2026
Read Mepolizumab reduces healthcare resource utilization in patients with chronic rhinosinusitis with nasal polyps: a linked EMR and claims-based pre-post study by Anna Swenson, Waseem Ahmed, Jared Silver, Shiyuan Zhang, Amy Edgecomb, Lingjiao Zhang, Rafael Alfonso-Cristancho, Richard Gliklich (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13602526.txt.
Description
Anna Swenson and colleagues report real-world results in 2026 for mepolizumab in patients with chronic rhinosinusitis with nasal polyps. This stubborn sinus condition involves polyps, blocked noses, and lost smell, and trials had shown the antibody drug helps. What routine practice added was unclear. Using linked records and insurance claims from United States clinician networks, the team compared each patient's care use and symptoms before and after starting the drug.
Within six months, visits fell across the board, including ear, nose and throat and allergy appointments. Fewer patients needed oral corticosteroid prescriptions, dropping from 36 to 27 percent, and oral antibiotics fell from 38 to 23 percent. Charted symptoms improved too: loss of smell was reported by 53 percent fewer patients, with facial pain, discharge, and obstruction also down. In everyday care, the authors conclude, the drug trims healthcare use and medication burden early.
Catalog record
| CREATOR | Anna Swenson, Waseem Ahmed, Jared Silver, Shiyuan Zhang, Amy Edgecomb, Lingjiao Zhang, Rafael Alfonso-Cristancho, Richard Gliklich |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 35788 |
| LICENSE | https://creativecommons.org/publicdomain/zero/1.0 |
| RIGHTS | CC0 |
| SOURCE | Europe PMC |